AUTHOR=Satake Tomoyuki , Shibuki Taro , Watanabe Kazuo , Sasaki Mitsuhito , Imaoka Hiroshi , Mitsunaga Shuichi , Kojima Motohiro , Ikeda Masafumi TITLE=Case Report: Atezolizumab plus bevacizumab for combined hepatocellular-cholangiocarcinoma JOURNAL=Frontiers in Oncology VOLUME=13 YEAR=2023 URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1234113 DOI=10.3389/fonc.2023.1234113 ISSN=2234-943X ABSTRACT=

Combined hepatocellular cholangiocarcinoma (cHCC-CCA) is a rare subtype of primary liver cancers. Therapeutic strategies for patients with cHCC-CCA are limited, and no standard systemic treatment has been established for unresectable cHCC-CCA. Here, we present six cases of cHCC-CCA treated with atezolizumab plus bevacizumab. We observed three partial responses and one stable disease as the best responses; two of these patients were still being treated with atezolizumab plus bevacizumab at the time of reporting (at least five months of treatment), whereas the remaining two patients were unable to continue treatment owing to adverse events. Atezolizumab plus bevacizumab may be an effective treatment for unresectable cHCC-CCA.